CareDx Inc. reported third quarter 2025 revenue of $100.1 million, a 21% increase year-over-year. Testing services revenue was $72.2 million, up 19%, with testing services volume growing 13% to 50,300. GAAP net income reached $1.7 million, compared to a net loss of $10.6 million in the same period of 2024. Adjusted EBITDA was $15.3 million, rising from $6.9 million year-over-year. Non-GAAP net income was $14.9 million, with diluted non-GAAP net income per share at $0.28. As of September 30, 2025, the company held $194.2 million in cash, cash equivalents, and marketable securities, with no debt outstanding. Full year 2025 revenue is now expected to be $372 million to $376 million, and adjusted EBITDA is forecasted between $35 million and $39 million. Recent business developments include the appointment of Suresh Gunasekaran to the Board of Directors and Jeff Teuteberg, MD, as Chief Medical Officer, completion of the first Epic Aura implementation, launch of AlloSeq Tx11, and introduction of Score 7.0 analysis software.